Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis


Por: Müller J, Sharmin S, Lorscheider J, Ozakbas S, Karabudak R, Horakova D, Weinstock-Guttman B, Shaygannejad V, Etemadifar M, Alroughani R, Patti F, Eichau S, Prat A, Lugaresi A, Tomassini V, Kermode AG, Amato MP, Turkoglu R, Altintas A, Buzzard K, Soysal A, van der Walt A, Butzkueven H, Blanco Y, Gerlach O, Khoury SJ, Barnett M, John N, Lechner-Scott J, Foschi M, Surcinelli A, van Pesch V, Prevost J, Sa MJ, Maimone D, D'hooghe M, Hughes S, Hodgkinson S, McGuigan C, Cartechini E, Taylor B, Spitaleri D, Slee M, McCombe P, Yamout B, Benkert P, Kuhle J, Kappos L, Roos I, Kalincik T, Havrdova EK, Girard M, Duquette P, Fabis-Pedrini M, Carroll WM, Skibina O, Gouider R, Mrabet S, Ramo-Tello C, Solaro C, Habek M, Van Wijmeersch B, Ampapa R, Macdonell R, Oreja-Guevara C, de Gans K, Laureys G, Oh J, Garber J, Gray O, Agüera-Morales E, Sanchez-Menoyo JL, Castillo-Triviño T, Grigoriadis N, Petersen T, Hardy TA, Vucic S, Reddel S, Ramanathan S, Al-Asmi A, Simu M, Baghbanian SM, Poehlau D, Al-Harbi T, Rojas JI, Deri N, Lalive P, Cambron M, Csepany T, Shuey N, Willekens B, Shaw C, Decoo D, Massey J, Yaldizli Ö, Derfuss T and Granziera C

Publicada: 1 jun 2025 Ahead of Print: 1 abr 2025
Resumen:
Importance Progression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results. Objective To compare various definitions of PIRA. Design, Setting, and Participants This cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments. Exposure Three-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation). Main Outcome and Measure For each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over >= 5 years). Results Among 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months. Conclusion and Relevance Incidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.

Filiaciones:
Müller J:
 CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia

 Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia

 Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland

Sharmin S:
 CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia

 Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia

Lorscheider J:
 Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland

Ozakbas S:
 Izmir University of Economics, Medical Point Hospital, Konak/Izmir, Turkey

 Multiple Sclerosis Research Association, Izmir, Turkey

Karabudak R:
 Neurological Sciences - Department of Neurology Neuroimmunology Unit, Yeditepe Faculty of Medicine, Yeditepe University Hospitals, Istanbul, Turkey

Horakova D:
 Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic

Weinstock-Guttman B:
 Department of Neurology, Jacobs MS Center for Treatment and Research, Buffalo, New York

Shaygannejad V:
 Isfahan University of Medical Sciences, Isfahan, Iran

Etemadifar M:
 Neurology, Dr Etemadifar MS Institute, Isfahan, Iran

Alroughani R:
 Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait

Patti F:
 Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy

 UOS Sclerosi Multipla, AOU Policlinico "G Rodolico-San Marco," Catania, Italy

Eichau S:
 Department of Neurology, Hospital Universitario Virgen Macarena, Sevilla, Spain

Prat A:
 CHUM MS Center and Universite de Montreal, Montreal, Quebec, Canada

Lugaresi A:
 IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italia

 Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy

Tomassini V:
 Institute for Advanced Biomedical Technologies (ITAB), Department of Neurosciences, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy

Kermode AG:
 Perron Institute for Neurological and Translational Science, University of Western Australia, Nedlands, Western Australia, Australia

Amato MP:
 Department NEUROFARBA, University of Florence, Florence, Italy

 IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy

Turkoglu R:
 Department of Neurology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey

Altintas A:
 Department of Neurology, School of Medicine and Koc University Research Center for Translational Medicine (KUTTAM), Koc University, Istanbul, Turkey

Buzzard K:
 Department of Neurosciences, Box Hill Hospital, Melbourne, Victoria, Australia

 Eastern Health Clinical School, Monash University, Box Hill, Melbourne, Victoria, Australia

Soysal A:
 Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey

van der Walt A:
 Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia

Butzkueven H:
 Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia

Blanco Y:
 Center of Neuroimmunology, Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain

Gerlach O:
 Academic MS Center Zuyd, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, the Netherlands

 School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands

Khoury SJ:
 Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon

Barnett M:
 Brain and Mind Centre, Sydney, New South Wales, Australia

John N:
 Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia

 Department of Neurology, Monash Health, Clayton, Australia

Lechner-Scott J:
 Hunter Medical Research Institute, University Newcastle, Newcastle, Australia

Foschi M:
 Department of Neuroscience, MS Center, Neurology Unit, S. Maria delle Croci Hospital of Ravenna, Ravenna, Italy

Surcinelli A:
 AUSL Romagna, Department of Diagnostic Imaging, S. Maria delle Croci Hospital of Ravenna, Ravenna, Italy

van Pesch V:
 Department of Neurology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium

Prevost J:
 CSSS Saint-Jérôme, Saint-Jerome, Canada

Sa MJ:
 Department of Neurology, Centro Hospitalar Universitario de Sao Joao, Porto, Portugal

Maimone D:
 Centro Sclerosi Multipla, UOC Neurologia, Azienda Ospedaliera per l'Emergenza Cannizzaro, Catania, Italy

D'hooghe M:
 Department of Neurology, Nationaal MS Centrum, Melsbroek, Belgium

Hughes S:
 Royal Victoria Hospital, Belfast, United Kingdom

Hodgkinson S:
 Immune Tolerance Laboratory Ingham Institute and Department of Medicine, University of New South Wales, Sydney, New South Wales, Australia

McGuigan C:
 St Vincent's University Hospital, Dublin, Ireland

Cartechini E:
 Neurology Unit, P O Unico Macerata, ast Macerata, Macerata, Italy

Taylor B:
 Royal Hobart Hospital, Hobart, Australia

Spitaleri D:
 Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy

Slee M:
 College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia

McCombe P:
 Department of Neurology, University of Queensland, Brisbane, Queensland, Australia

Yamout B:
 Neurology Institute, Harley Street Medical Center, Abu Dhabi, United Arab Emirates

Benkert P:
 Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland

Kuhle J:
 Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland

Kappos L:
 Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland

Roos I:
 CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia

 Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia

Kalincik T:
 CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia

 Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia

Havrdova EK:
 Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic

Girard M:
 CHUM MS Center and Universite de Montreal, Montreal, Quebec, Canada

Duquette P:
 CHUM MS Center and Universite de Montreal, Montreal, Quebec, Canada

Fabis-Pedrini M:
 Perron Institute for Neurological and Translational Science, University of Western Australia, Nedlands, Western Australia, Australia

Carroll WM:
 Perron Institute for Neurological and Translational Science, University of Western Australia, Nedlands, Western Australia, Australia

Skibina O:
 Department of Neurosciences, Box Hill Hospital, Melbourne, Victoria, Australia

Gouider R:
 Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi University Hospital, Tunis, Tunisia

Mrabet S:
 Department of Neuroscience, Hospital Germans Trias i Pujol, Badalona, Spain

:
 Department of Neuroscience, Hospital Germans Trias i Pujol, Badalona, Spain

Solaro C:
 Department of Neurology, ASL3 Genovese, Genova, Italy

Habek M:
 Department of Neurology, University Hospital Center Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia

Van Wijmeersch B:
 University MS Centre, Hasselt-Pelt, Noorderhart, Rehabilitation & MS, Pelt and Hasselt University, Hasselt, Belgium

Ampapa R:
 Nemocnice Jihlava, Jihlava, Czech Republic

Macdonell R:
 Austin Health, Melbourne, Victoria, Australia

Oreja-Guevara C:
 Department of Neurology, Hospital Clínico Universitario San Carlos, IdISSC, Madrid, Spain

de Gans K:
 Groene Hart Ziekenhuis, Gouda, the Netherlands

Laureys G:
 Department of Neurology, University Hospital Ghent, Ghent, Belgium

Oh J:
 St Michael's Hospital, Toronto, Ontario, Canada

Garber J:
 Department of Neurology, Westmead Hospital, Sydney, New South Wales, Australia

Gray O:
 South Eastern HSC Trust, Belfast, United Kingdom

Agüera-Morales E:
 Department of Medicine and Surgery, University Hospital Reina Sofia, Cordoba, Spain

Sanchez-Menoyo JL:
 Department of Neurology, Hospital de Galdakao-Usansolo, Galdakao, Spain

Castillo-Triviño T:
 Hospital Universitario Donostia, San Sebastián, Spain

Grigoriadis N:
 Department of Neurology, Faculty of Medicine, AHEPA University Hospital, Thessaloniki, Greece

Petersen T:
 Aarhus University Hospital, Arhus C, Aarhus, Denmark

Hardy TA:
 Department of Neurology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia

Vucic S:
 Department of Neurology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia

Reddel S:
 Department of Neurology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia

Ramanathan S:
 Translational Neuroimmunology Group, Kids Neuroscience Centre and Brain and Mind Centre, Sydney, New South Wales, Australia

 Faculty of Medicine and Health, Sydney Medical School, Concord Repatriation General Hospital, Sydney, New South Wales, Australia

Al-Asmi A:
 College of Medicine & Health Sciences and Sultan Qaboos University Hospital, Sultan Qaboos University, Al-Khodh, Oman

Simu M:
 Department of Neurology, Timisoara, Romania

Baghbanian SM:
 Department of Neurology, Booalisina Hospital, Sari, Iran

Poehlau D:
 Multiple Sclerosis Centre Kamillus-Klinik, Asbach, Germany

Al-Harbi T:
 Neurology Department, King Fahad Specialist Hospital-Dammam, Khobar, Saudi Arabia

Rojas JI:
 Hospital Universitario de CEMIC, Buenos Aires, Argentina

Deri N:
 Department of Neurology, Hospital Fernandez, Capital Federal, Argentina

Lalive P:
 Unit of Neuroimmunology, Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospital, Geneva, Switzerland

Cambron M:
 Neurology, Az Sint-Jan Brugge, Bruges, Belgium

Csepany T:
 Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

Shuey N:
 St. Vincent's Hospital, Fitzroy, Melbourne, Victoria, Australia

Willekens B:
 Department of Neurology, Antwerp University Hospital, Edegem, Belgium

 Translational Neurosciences Research Group, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

Shaw C:
 Department of Neuroscience, Barwon Health, Geelong, Australia

Decoo D:
 AZ Alma Ziekenhuis, Sijsele, Damme, Belgium

Massey J:
 St. Vincent's Hospital Sydney, Sydney, New South Wales, Australia

Yaldizli Ö:
 Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland

Derfuss T:
 Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland

Granziera C:
 Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland
ISSN: 21686149





JAMA Neurology
Editorial
American Medical Association, 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 82 Número: 6
Páginas: 614-625
WOS Id: 001470351300001
ID de PubMed: 40227706
imagen Green Submitted

MÉTRICAS